This is an aggregated industry headline. Read the full story at STAT News →
STAT+: Pharmalittle: We’re reading about a review of Alzheimer’s drugs, FDA interest in compounded peptides, and more
The FDA will convene an outside panel of advisers to discuss whether to allow compounding pharmacies to manufacture certain peptides
By STAT News
· Apr 16, 2026
· via STAT News
Image: STAT News
Tags
theweekformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
For Meghan O'Hora, pharma marketing isn't about patients. It's about people and making real connections that h…
The WeekFierceBiotech ↗
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-r…
The WeekBriefing
The agency’s Complete Response Letter delays CTx‑1301, the biotech’s first commercial hopeful, over CMC issues…